Form 4: Liquidia CEO Roger Jeffs Sells Shares via 10b5-1 Plan

Liquidia Corporation CEO Roger Jeffs sold 53,300 shares of common stock over three days in April 2026 under a pre-arranged trading plan.

Summary

• CEO Roger Jeffs sold a total of 53,300 shares of Liquidia Corp common stock between April 14 and April 16, 2026.
• The sales were executed under a Rule 10b5-1 trading plan adopted on November 5, 2025.
• Shares were sold at weighted average prices ranging from $40.00 to $40.312 per share.
• Following these transactions, the reporting person retains beneficial ownership of 1,441,934 shares held through Serendipity BioPharma LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were executed via a pre-planned 10b5-1 arrangement, which is standard practice for executive liquidity.

Positives

• The transactions were conducted under a pre-established Rule 10b5-1 plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The sale represents a reduction in the CEO's indirect beneficial ownership stake in the company.

Risks

• Executive stock sales can sometimes be perceived negatively by retail investors as a signal of reduced confidence in future share price appreciation.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that executive selling under 10b5-1 plans is a routine corporate governance practice in the biopharmaceutical sector, often used for personal financial planning rather than reflecting a change in company outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives at companies like United Therapeutics or MannKind to manage equity holdings while maintaining regulatory compliance.

Related Party Transactions

• The reporting person holds shares through the Roger A. Jeffs Living Trust and Serendipity BioPharma LLC, where he serves as trustee and manager, respectively.

Stakeholder Impact

• Minimal impact expected as the sales were pre-planned and represent a small portion of the CEO's total holdings.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Liquidia, LQDA, Insider Trading, Form 4, Roger Jeffs, Biopharma, Stock Sale